PeptidesInfo
Benefits

NAD+: What It Is, and What the Human Evidence Actually Shows

NAD+ is sold as drips, shots and supplements for energy and aging. Precursor pills really do raise NAD+ in blood - but the benefit trials are mostly small and mixed, and direct NAD+ infusions have almost no published human data. Here is the honest picture.

Abstract lattice illustration for the NAD+ evidence article
Contents
  1. What NAD+ actually is
  2. The part that is well documented
  3. The part that is not proven
  4. What about NAD+ drips and injections?
  5. The honest bottom line

Key findings

  1. 1NAD+ is a real, essential molecule found in every living cell, and blood levels can be raised by taking precursors such as NR and NMN - that part is well documented in randomized trials.
  2. 2Raising the level is not the same as fixing a problem. Trials measuring outcomes like insulin sensitivity, blood pressure and physical performance report small, mixed, or null results overall.
  3. 3One well-known NMN trial found improved muscle insulin sensitivity in prediabetic women - a real but narrow result in a specific group, not proof of general anti-aging effects.
  4. 4Direct NAD+ drips and injections, the form sold by clinics, have almost no published human efficacy trials behind them.
  5. 5Nothing in this category is FDA-approved to treat any condition, so product quality and dosing claims are not independently verified.

Evidence level

Preliminary evidence

Human trials show that NAD+ precursor supplements (NR and NMN) reliably raise NAD+ levels in blood and are well tolerated over weeks to months. What they have not consistently shown is improvement in the outcomes people take them for - energy, metabolism, aging markers - where results are small, mixed, or null. Direct NAD+ infusions and injections have almost no published efficacy data in people.

Regulatory status

Not FDA-approved

NAD+ and its precursors are not FDA-approved to treat any disease or condition. They are sold as supplements or compounded infusions, categories where product content and quality are not verified by a regulator before sale.

NAD+ is having a moment: IV drips at longevity clinics, injection vials online, precursor pills with "cellular energy" claims. The molecule itself is completely real and genuinely essential. The open question is whether adding more of it does what the marketing says. The short answer from human trials: levels go up, outcomes mostly don't - at least not yet.

What NAD+ actually is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme - a helper molecule - found in every living cell. It shuttles electrons in the reactions that turn food into usable energy, and it is a required ingredient for enzymes that repair DNA and regulate how cells age.

Two facts drive all the interest. First, cells cannot run without it. Second, several studies report that NAD+ levels decline with age in some tissues. From there, the marketing leap is short: if less NAD+ comes with aging, more NAD+ should push the other way. That leap is exactly what the human trials set out to test.

The part that is well documented

You genuinely can raise blood NAD+ levels by mouth. Randomized trials of the precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) - molecules the body converts into NAD+ - consistently show meaningful increases in blood NAD+ within weeks, with good short-term tolerability[2][4].

In one placebo-controlled trial, six weeks of NR raised blood NAD+ by about 60% in healthy older adults[2]. A 140-person safety trial found dose-dependent increases with side effects similar to placebo over eight weeks[4]. So "it raises your NAD+" is a fair claim for the precursor pills.

The part that is not proven

When trials measure real outcomes, results have been small, narrow, or null:

  • Insulin sensitivity, in one specific group. The best-known positive result: 10 weeks of NMN improved muscle insulin sensitivity in a small trial of postmenopausal women with prediabetes[1]. It is a real, peer-reviewed finding - and a narrow one. The same trial found no change in body composition or blood pressure, and it says nothing about healthy people or men.
  • Null results in a stronger-dosed trial. In obese, insulin-resistant men, 12 weeks of high-dose NR did not improve insulin sensitivity or the other key metabolic endpoints at all[3].
  • Suggestive but unproven cardiovascular signals. The NR trial in older adults saw hints of lower blood pressure and arterial stiffness, but the study was too small to be conclusive, and the authors said so[2].

Notice what is missing from that list: energy, focus, endurance, skin, lifespan - the headline uses in the ads. For those, controlled human evidence is essentially absent or unconvincing so far.

What about NAD+ drips and injections?

Here the gap between marketing and evidence is widest. The infusions sold by clinics deliver NAD+ itself, not a precursor - and published human research on that approach is close to nonexistent. A handful of small pharmacokinetic studies describe how infused NAD+ moves through blood and urine, but there are no completed, published efficacy trials showing that drips or injections improve any health outcome. Anyone stating otherwise is citing evidence that does not exist yet.

There is also a practical point: nothing in this category - precursor, drip, or vial - is FDA-approved to treat anything. Supplements and compounded infusions are not checked by a regulator for content or purity before sale, which is the same third-party-testing problem covered in our guide to purity and Certificates of Analysis.

The honest bottom line

NAD+ biology is a serious, active research field, and the precursor trials are real science with real (if modest) results. But as of today: precursors reliably raise NAD+ levels; benefit trials are small and mixed, with one narrow metabolic win and several nulls; and direct NAD+ infusion has effectively no efficacy data in people. "Preliminary" is the honest grade. If large trials change that picture, this page will change with them.

References

Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.

  1. 1.

    Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Science (Yoshino M, Yoshino J, Kayser BD, et al.), 2021.

    Randomized controlled trialPostmenopausal women with prediabetes and overweight or obesityn = 25

    Result: Randomized, placebo-controlled trial of 250 mg/day NMN for 10 weeks. NMN increased muscle insulin sensitivity (measured by clamp) versus placebo, but did not change body composition, blood pressure, or several other metabolic measures.

    ↑ back to text
  2. 2.

    Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults Nature Communications (Martens CR, Denman BA, Mazzo MR, et al.), 2018.

    Randomized controlled trialHealthy middle-aged and older adults (55-79)n = 24

    Result: Crossover trial of 1,000 mg/day NR for 6 weeks. NR raised blood NAD+ by about 60% and was well tolerated. Effects on blood pressure and arterial stiffness were suggestive but not statistically conclusive in this small sample.

    ↑ back to text
  3. 3.

    A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men - safety, insulin-sensitivity, and lipid-mobilizing effects American Journal of Clinical Nutrition (Dollerup OL, Christensen B, Svart M, et al.), 2018.

    Randomized controlled trialObese, insulin-resistant menn = 40

    Result: 12 weeks of 2,000 mg/day NR was safe but did not improve insulin sensitivity or other key metabolic endpoints versus placebo.

    ↑ back to text
  4. 4.

    Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults Scientific Reports (Conze D, Brenner C, Kruger CL), 2019.

    Randomized controlled trialHealthy overweight adultsn = 140

    Result: 8 weeks of NR at 100, 300 and 1,000 mg/day dose-dependently raised blood NAD+ with a safety profile similar to placebo.

    ↑ back to text

Advertising disclosure: ads on this page are for NuNu Research, a research-use-only chemical storefront that shares an owner with PeptidesInfo. Ads never influence the evidence grades, regulatory statuses, or conclusions above, which come solely from the cited primary sources.

Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.

NAD+nicotinamide mononucleotidenicotinamide ribosidehealthy agingenergy

Comments

Have a question, or a study to add? Join the discussion — no account needed. Comments are moderated before they appear.

Continue researching

Related analyses, profiles, and research areas

Recommendations are ranked by shared peptides, research areas, evidence level, and topic tags — not by popularity.

Research analysis5 min read

CJC-1295 and Ipamorelin: Growth Hormone Research and Unanswered Risks

The 'CJC/ipa' stack is sold for muscle, fat loss, sleep and anti-aging. The human evidence is a handful of short hormone-level studies, two abandoned development programmes, and no outcome trials — plus a set of risks that have never been studied because the trials were never run.

Research analysis5 min read

GLP-1 Peptides: Established Uses Versus Emerging Research

Semaglutide and tirzepatide are the best-evidenced peptides in medicine — for specific uses. We separate the approved indications with large trials from the emerging research (kidney, liver, heart failure, sleep apnoea, Alzheimer's) and the open questions about regain, muscle loss and compounded products.

Benefits3 min read

Sermorelin: Benefits, Uses, and What the Evidence Shows

Sermorelin nudges your body to make its own growth hormone. It was once FDA-approved for children's growth, and is now used off-label for anti-aging and body composition. The direct human evidence is limited but promising. Here's the honest read.

Benefits4 min read

Peptides for Energy and Sleep: Claims Versus Trials

Better sleep and more energy are standard peptide selling points. No growth-hormone secretagogue has been tested with sleep laboratory measurement, and the one peptide with a large sleep trial works by a completely different route.